The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization.
麻豆原创 Analysis and Insights: Global Biologics Drug Discovery 麻豆原创
The global Biologics Drug Discovery market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Biologics Drug Discovery market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biologics Drug Discovery, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biologics Drug Discovery, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics Drug Discovery revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics Drug Discovery market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Biologics Drug Discovery revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
GenScript
Roche
Pfizer
Novartis
Sanofi
Merck
GlaxoSmithKline
AstraZeneca
AbbVie
Amgen
Bristol-Myers Squibb
Novo Nordisk
Allergan
Astellas Pharma
Teva Pharmaceutical Industries
Segment by Type
Biologicals
Monoclonal Antibodies
Recombinant Proteins
Other Biologics
Segment by Application
Hospitals
Clinics
Research Labs
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Biologics Drug Discovery in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics Drug Discovery companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics Drug Discovery revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Biologics Drug Discovery 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Biologicals
1.2.3 Monoclonal Antibodies
1.2.4 Recombinant Proteins
1.2.5 Other Biologics
1.3 麻豆原创 by Application
1.3.1 Global Biologics Drug Discovery 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Labs
1.3.5 Diagnostic Centers
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biologics Drug Discovery 麻豆原创 Perspective (2019-2030)
2.2 Global Biologics Drug Discovery Growth Trends by Region
2.2.1 Biologics Drug Discovery 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biologics Drug Discovery Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Biologics Drug Discovery Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Biologics Drug Discovery 麻豆原创 Dynamics
2.3.1 Biologics Drug Discovery Industry Trends
2.3.2 Biologics Drug Discovery 麻豆原创 Drivers
2.3.3 Biologics Drug Discovery 麻豆原创 Challenges
2.3.4 Biologics Drug Discovery 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Biologics Drug Discovery by Players
3.1.1 Global Biologics Drug Discovery Revenue by Players (2019-2024)
3.1.2 Global Biologics Drug Discovery Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Biologics Drug Discovery 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Biologics Drug Discovery, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Biologics Drug Discovery 麻豆原创 Concentration Ratio
3.4.1 Global Biologics Drug Discovery 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biologics Drug Discovery Revenue in 2023
3.5 Global Key Players of Biologics Drug Discovery Head office and Area Served
3.6 Global Key Players of Biologics Drug Discovery, Product and Application
3.7 Global Key Players of Biologics Drug Discovery, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biologics Drug Discovery Breakdown Data by Type
4.1 Global Biologics Drug Discovery Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Biologics Drug Discovery Forecasted 麻豆原创 Size by Type (2025-2030)
5 Biologics Drug Discovery Breakdown Data by Application
5.1 Global Biologics Drug Discovery Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Biologics Drug Discovery Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Biologics Drug Discovery 麻豆原创 Size (2019-2030)
6.2 North America Biologics Drug Discovery 麻豆原创 Size by Type
6.2.1 North America Biologics Drug Discovery 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Biologics Drug Discovery 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Biologics Drug Discovery 麻豆原创 Share by Type (2019-2030)
6.3 North America Biologics Drug Discovery 麻豆原创 Size by Application
6.3.1 North America Biologics Drug Discovery 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Biologics Drug Discovery 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Biologics Drug Discovery 麻豆原创 Share by Application (2019-2030)
6.4 North America Biologics Drug Discovery 麻豆原创 Size by Country
6.4.1 North America Biologics Drug Discovery 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Biologics Drug Discovery 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Biologics Drug Discovery 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Biologics Drug Discovery 麻豆原创 Size (2019-2030)
7.2 Europe Biologics Drug Discovery 麻豆原创 Size by Type
7.2.1 Europe Biologics Drug Discovery 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Biologics Drug Discovery 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Biologics Drug Discovery 麻豆原创 Share by Type (2019-2030)
7.3 Europe Biologics Drug Discovery 麻豆原创 Size by Application
7.3.1 Europe Biologics Drug Discovery 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Biologics Drug Discovery 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Biologics Drug Discovery 麻豆原创 Share by Application (2019-2030)
7.4 Europe Biologics Drug Discovery 麻豆原创 Size by Country
7.4.1 Europe Biologics Drug Discovery 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Biologics Drug Discovery 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Biologics Drug Discovery 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Biologics Drug Discovery 麻豆原创 Size (2019-2030)
8.2 China Biologics Drug Discovery 麻豆原创 Size by Type
8.2.1 China Biologics Drug Discovery 麻豆原创 Size by Type (2019-2024)
8.2.2 China Biologics Drug Discovery 麻豆原创 Size by Type (2025-2030)
8.2.3 China Biologics Drug Discovery 麻豆原创 Share by Type (2019-2030)
8.3 China Biologics Drug Discovery 麻豆原创 Size by Application
8.3.1 China Biologics Drug Discovery 麻豆原创 Size by Application (2019-2024)
8.3.2 China Biologics Drug Discovery 麻豆原创 Size by Application (2025-2030)
8.3.3 China Biologics Drug Discovery 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Biologics Drug Discovery 麻豆原创 Size (2019-2030)
9.2 Asia Biologics Drug Discovery 麻豆原创 Size by Type
9.2.1 Asia Biologics Drug Discovery 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Biologics Drug Discovery 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Biologics Drug Discovery 麻豆原创 Share by Type (2019-2030)
9.3 Asia Biologics Drug Discovery 麻豆原创 Size by Application
9.3.1 Asia Biologics Drug Discovery 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Biologics Drug Discovery 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Biologics Drug Discovery 麻豆原创 Share by Application (2019-2030)
9.4 Asia Biologics Drug Discovery 麻豆原创 Size by Region
9.4.1 Asia Biologics Drug Discovery 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Biologics Drug Discovery 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Biologics Drug Discovery 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Biologics Drug Discovery 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 GenScript
11.1.1 GenScript Company Details
11.1.2 GenScript Business Overview
11.1.3 GenScript Biologics Drug Discovery Introduction
11.1.4 GenScript Revenue in Biologics Drug Discovery Business (2019-2024)
11.1.5 GenScript Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Biologics Drug Discovery Introduction
11.2.4 Roche Revenue in Biologics Drug Discovery Business (2019-2024)
11.2.5 Roche Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Biologics Drug Discovery Introduction
11.3.4 Pfizer Revenue in Biologics Drug Discovery Business (2019-2024)
11.3.5 Pfizer Recent Developments
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Biologics Drug Discovery Introduction
11.4.4 Novartis Revenue in Biologics Drug Discovery Business (2019-2024)
11.4.5 Novartis Recent Developments
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Biologics Drug Discovery Introduction
11.5.4 Sanofi Revenue in Biologics Drug Discovery Business (2019-2024)
11.5.5 Sanofi Recent Developments
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Biologics Drug Discovery Introduction
11.6.4 Merck Revenue in Biologics Drug Discovery Business (2019-2024)
11.6.5 Merck Recent Developments
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Details
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Biologics Drug Discovery Introduction
11.7.4 GlaxoSmithKline Revenue in Biologics Drug Discovery Business (2019-2024)
11.7.5 GlaxoSmithKline Recent Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Biologics Drug Discovery Introduction
11.8.4 AstraZeneca Revenue in Biologics Drug Discovery Business (2019-2024)
11.8.5 AstraZeneca Recent Developments
11.9 AbbVie
11.9.1 AbbVie Company Details
11.9.2 AbbVie Business Overview
11.9.3 AbbVie Biologics Drug Discovery Introduction
11.9.4 AbbVie Revenue in Biologics Drug Discovery Business (2019-2024)
11.9.5 AbbVie Recent Developments
11.10 Amgen
11.10.1 Amgen Company Details
11.10.2 Amgen Business Overview
11.10.3 Amgen Biologics Drug Discovery Introduction
11.10.4 Amgen Revenue in Biologics Drug Discovery Business (2019-2024)
11.10.5 Amgen Recent Developments
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Company Details
11.11.2 Bristol-Myers Squibb Business Overview
11.11.3 Bristol-Myers Squibb Biologics Drug Discovery Introduction
11.11.4 Bristol-Myers Squibb Revenue in Biologics Drug Discovery Business (2019-2024)
11.11.5 Bristol-Myers Squibb Recent Developments
11.12 Novo Nordisk
11.12.1 Novo Nordisk Company Details
11.12.2 Novo Nordisk Business Overview
11.12.3 Novo Nordisk Biologics Drug Discovery Introduction
11.12.4 Novo Nordisk Revenue in Biologics Drug Discovery Business (2019-2024)
11.12.5 Novo Nordisk Recent Developments
11.13 Allergan
11.13.1 Allergan Company Details
11.13.2 Allergan Business Overview
11.13.3 Allergan Biologics Drug Discovery Introduction
11.13.4 Allergan Revenue in Biologics Drug Discovery Business (2019-2024)
11.13.5 Allergan Recent Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Details
11.14.2 Astellas Pharma Business Overview
11.14.3 Astellas Pharma Biologics Drug Discovery Introduction
11.14.4 Astellas Pharma Revenue in Biologics Drug Discovery Business (2019-2024)
11.14.5 Astellas Pharma Recent Developments
11.15 Teva Pharmaceutical Industries
11.15.1 Teva Pharmaceutical Industries Company Details
11.15.2 Teva Pharmaceutical Industries Business Overview
11.15.3 Teva Pharmaceutical Industries Biologics Drug Discovery Introduction
11.15.4 Teva Pharmaceutical Industries Revenue in Biologics Drug Discovery Business (2019-2024)
11.15.5 Teva Pharmaceutical Industries Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
GenScript
Roche
Pfizer
Novartis
Sanofi
Merck
GlaxoSmithKline
AstraZeneca
AbbVie
Amgen
Bristol-Myers Squibb
Novo Nordisk
Allergan
Astellas Pharma
Teva Pharmaceutical Industries
听
听
*If Applicable.
